ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Acoramidis (Beyonttra)

For the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

CHMP opinion 12 Dec 2024 → EU licence 10 Feb 2025 · Bayer AG 

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.